West Pharmaceutical Services, Inc.

NYSE:WST Stock Report

Market Cap: US$24.0b

West Pharmaceutical Services Past Earnings Performance

Past criteria checks 2/6

West Pharmaceutical Services has been growing earnings at an average annual rate of 13.8%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 9.8% per year. West Pharmaceutical Services's return on equity is 18.2%, and it has net margins of 17.4%.

Key information

13.8%

Earnings growth rate

13.8%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate9.8%
Return on equity18.2%
Net Margin17.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?

Nov 15
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?

West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 27
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next

West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense

Oct 11

Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely

Sep 20
Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely

A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

Sep 02
A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 28
West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)

Jul 25

Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?

Jul 15
Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?

We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt

Jun 27
We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt

Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

May 21
Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)

West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry

May 11

West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price

Mar 30
West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price

Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?

Mar 12
Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?

Why West Pharma Is Far From Done

Feb 28

West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price

Feb 20
West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price

West Pharmaceutical Services: Still Too Expensive After The Recent Drop

Feb 20

What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?

Jan 10
What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?

West Pharmaceutical: Great Business, Not So Great Valuation

Jan 08

West Pharmaceutical Services: The Run Might Be Over

Oct 18

West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics

Aug 08

West Pharmaceutical: Hard To Justify The Price

May 26

West Pharmaceutical Q4 2022 Earnings Preview

Feb 15

West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive

Dec 19

West Pharmaceutical declares $0.19 dividend

Dec 13

Revenue & Expenses Breakdown

How West Pharmaceutical Services makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:WST Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,87650034269
30 Jun 242,87752534970
31 Mar 242,92956935569
31 Dec 232,95059335468
30 Sep 232,92755929966
30 Jun 232,86651932663
31 Mar 232,88455231961
31 Dec 222,88758631659
30 Sep 222,90963137756
30 Jun 222,92968635256
31 Mar 222,88168436255
31 Dec 212,83266235653
30 Sep 212,68161334052
30 Jun 212,52351931051
31 Mar 212,32642330848
31 Dec 202,14734630147
30 Sep 202,03731229144
30 Jun 201,94528629741
31 Mar 201,88826127740
31 Dec 191,84024227339
30 Sep 191,79223026239
30 Jun 191,76722925939
31 Mar 191,74521925841
31 Dec 181,71720725640
30 Sep 181,71115525740
30 Jun 181,67715125639
31 Mar 181,62713324838
31 Dec 171,59915124339
30 Sep 171,56619024539
30 Jun 171,54417624239
31 Mar 171,53518224338
31 Dec 161,50914423837
30 Sep 161,48713824137
30 Jun 161,45410223837
31 Mar 161,4268524636
31 Dec 151,4009624334
30 Sep 151,3909424032
30 Jun 151,40112324133
31 Mar 151,41113322835
31 Dec 141,42112722937
30 Sep 141,41411923039
30 Jun 141,40011523039
31 Mar 141,37610823239
31 Dec 131,36811223538

Quality Earnings: WST has high quality earnings.

Growing Profit Margin: WST's current net profit margins (17.4%) are lower than last year (19.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: WST's earnings have grown by 13.8% per year over the past 5 years.

Accelerating Growth: WST's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: WST had negative earnings growth (-10.7%) over the past year, making it difficult to compare to the Life Sciences industry average (-4.7%).

Return on Equity

High ROE: WST's Return on Equity (18.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

West Pharmaceutical Services, Inc. is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Lawrence MarshBarclays
Michael RyskinBofA Global Research